CDK5 inhibitor 20-223|cas:865317-30-2|西域试剂

CDK5 inhibitor 20-223,99.64%

产品编号：Bellancom-123772| CAS NO：865317-30-2| 分子式：C₁₉H₁₉N₃O| 分子量：305.37

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-123772	￥2000.00	杭州北京（现货）
Bellancom-123772	￥3500.00	杭州北京（现货）
Bellancom-123772	￥6500.00	杭州北京（现货）
Bellancom-123772	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CDK5 inhibitor 20-223

产品介绍

CDK5 inhibitor 20-223 是一种有效的 CDK2 和 CDK5 抑制剂，IC₅₀ 分别为 6.0 和 8.8 nM。CDK5 inhibitor 20-223 有潜力用于结肠直肠癌 (CRC) 的研究。

生物活性

CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent.

体外研究

CDK5 inhibitor 20-223 (10 nM-10 μM; 72 hours) potently inhibits cell growth in a panel of colorectal cancer (CRC) cell lines.
CDK5 inhibitor 20-223 (0.3125-20 μM; 6 hours) induces a dose-dependent decrease in pRB (S807/811) and pFAK (S732) levels in each of the three CRC cell lines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	CRC cell lines SW620, DLD1, HT29, HCT116, FET, CBS, and GEO cells
Concentration:	10 μM, 1 μM, 100 nM, 10 nM
Incubation Time:	72 hours
Result:	Reduced cell growth. IC50s of 168±20, 480±41, 360±72, 763±92, 117±49, 568±49, 79±31 nM for SW620, DLD1, HT29, HCT116, FET, CBS, and GEO cells.

Western Blot Analysis

Cell Line:	CRC cell lines GEO, HCT116 and HT29
Concentration:	20, 10, 5, 2.5, 1.25, 0.625, 0.3125 μM
Incubation Time:	6 hours
Result:	Did not affect the total levels of CDK2/5, and the levels of total FAK or total Retinoblastoma protein (Rb). Induced a dose-dependent decrease in pRB (S807/811) and pFAK (S732) levels.

体内研究
(In Vivo)

CDK5 inhibitor 20-223 (8mg/kg; subcutaneously; for 14 injections) shows anti-tumor activity in human CRC xenograft tumors in nude mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice
Dosage:	8 mg/kg
Administration:	Injections were given subcutaneously daily for the first week and every other day for two more weeks for a total of 14 injections.
Result:	Reduced tumor growth and tumor weight in vivo.

体内研究

CDK5 inhibitor 20-223 (8mg/kg; subcutaneously; for 14 injections) shows anti-tumor activity in human CRC xenograft tumors in nude mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice
Dosage:	8 mg/kg
Administration:	Injections were given subcutaneously daily for the first week and every other day for two more weeks for a total of 14 injections.
Result:	Reduced tumor growth and tumor weight in vivo.

体内研究

CDK5 inhibitor 20-223 (8mg/kg; subcutaneously; for 14 injections) shows anti-tumor activity in human CRC xenograft tumors in nude mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice
Dosage:	8 mg/kg
Administration:	Injections were given subcutaneously daily for the first week and every other day for two more weeks for a total of 14 injections.
Result:	Reduced tumor growth and tumor weight in vivo.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (327.47 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2747 mL	16.3736 mL	32.7472 mL
5 mM	0.6549 mL	3.2747 mL	6.5494 mL
10 mM	0.3275 mL	1.6374 mL	3.2747 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 5 mg/mL (16.37 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (16.37 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。